Please ensure Javascript is enabled for purposes of website accessibility

Moderna Says It's on Pace to Deliver 100 Million Coronavirus Vaccine Doses to Feds by the end of Q1

By Eric Volkman - Jan 26, 2021 at 5:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company also increased its global production forecast for 2021.

In a business update published on Tuesday, Moderna (MRNA 0.70%) said that it's still on pace to deliver 100 million doses of its mRNA-1273 coronavirus vaccine to the U.S. federal government by the end of the first quarter (March 31). The company added that it should have a total of 200 million available by the conclusion of the following quarter (June 30).

So far, Moderna has shipped 30.4 million doses. Citing the government's Centers for Disease Control and Prevention, the company added that roughly 10.1 million have been administered to Americans so far.

Child getting a jab from a medical professional.

Image source: Getty Images.

The government has committed to buying 200 million mRNA-1273 doses; it also holds an option for an additional 300 million if necessary.

President Joe Biden has set an ambitious target of 100 million vaccinations in his administration's first 100 days. As mRNA-1273 is one of only two vaccines to be authorized for emergency use by the Food and Drug Administration (FDA) -- the other is BNT162b2 from Pfizer and BioNTech -- it will be an integral part of this effort.

Zooming out to a global scale, Moderna said that it has lifted its base case production estimate for 2021. This now stands at 600 million from the former 500 million doses. The company is currently hiring staff in order to reach a goal of producing up to 1 billion doses over the course of this year.

Moderna's update is good news for the fight against the coronavirus and consequently good news for the stock. On Tuesday, the company's shares rose by 3.4% in contrast to the slump of the S&P 500 index.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
BioNTech SE Stock Quote
BioNTech SE
BNTX
$134.04 (1.32%) $1.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.